From: The association between ambient UVB dose and ANCA-associated vasculitis relapse and onset
Characteristics | Total | GPA | MPA | EGPA | p |
---|---|---|---|---|---|
n (%) | 439 | 196 (44.6) | 220 (50.1) | 23 (5.2) | |
Age (years, median [IQR]) | 59.0 [48.0, 69.0] | 54.0 [40.0, 62.3] | 65.0 [54.0, 73.0] | 57.0 [51.5, 62.5] | < 0.001 |
Male (%) | 253 (57.6) | 112 (57.1) | 129 (58.6) | 12 (52.2) | 0.823 |
Ethnicity (%) | 0.353 | ||||
White | 433 (98.6) | 194 (99.0) | 217 (98.6) | 22 (95.7) | |
Asian | 6 (1.4) | 2 (1.0) | 3 (1.4) | 1 (4.3) | |
ANCA subtype (ELISA) (%) | < 0.001 | ||||
PR3 | 219 (49.9) | 170 (86.7) | 45 (20.5) | 4 (17.4) | |
MPO | 207 (47.2) | 19 (9.7) | 172 (78.2) | 16 (69.6) | |
ELISA-negative | 12 (2.7) | 6 (3.1) | 3 (1.4) | 3 (13.0) | |
No ELISA recorded | 1 (0.2) | 1 (0.5) | 0 (0.0) | 0 (0.0) | |
Organ involvement (%) | |||||
Musculoskeletal | 168 (38.3) | 103 (52.6) | 53 (24.1) | 12 (52.2) | < 0.001 |
Mucocutaneous | 115 (26.2) | 71 (36.2) | 34 (15.5) | 10 (43.5) | < 0.001 |
Eyes | 57 (13.0) | 37 (18.9) | 18 (8.2) | 2 (8.7) | 0.004 |
Lung | 229 (52.2) | 132 (67.3) | 78 (35.5) | 19 (82.6) | < 0.001 |
Neurological | 60 (13.7) | 27 (13.8) | 22 (10.0) | 11 (47.8) | < 0.001 |
Ears, nose, throat | 193 (44.0) | 147 (75.0) | 29 (13.2) | 17 (73.9) | < 0.001 |
Cardiovascular | 12 (2.7) | 6 (3.1) | 6 (2.7) | 0 (0.0) | 1 |
Kidney | 370 (84.3) | 146 (74.5) | 212 (96.4) | 12 (52.2) | < 0.001 |
Gastrointestinal | 25 (5.7) | 13 (6.6) | 11 (5.0) | 1 (4.3) | 0.828 |
Latitude (degrees, median [IQR]) | 53.30 [52.67, 53.39] | 53.29 [52.67, 53.39] | 53.32 [52.76, 53.39] | 53.29 [52.86, 53.37] | 0.350 |
Longitude (degrees, median [IQR]) | − 6.39 [− 7.77, − 6.30] | − 6.43 [− 8.37, − 6.27] | − 6.48 [− 8.35, − 6.22] | − 6.39 [− 7.77, − 6.30] | 0.684 |
CW-D-UVB at symptom onset (kJ/m2, median [IQR]) | 75.98 [19.12, 161.06] | 78.46 [20.29, 166.07] | 74.57 [18.94, 153.51] | 60.41 [30.27, 115.27] | 0.842 |
Season of diagnosis (%) | 0.502 | ||||
Spring | 129 (29.4) | 60 (30.6) | 67 (30.5) | 2 (8.7) | |
Summer | 92 (21.0) | 41 (20.9) | 44 (20.0) | 7 (30.4) | |
Autumn | 112 (25.5) | 48 (24.5) | 57 (25.9) | 7 (30.4) | |
Winter | 106 (24.1) | 47 (24.0) | 52 (23.6) | 7 (30.4) | |
Follow-up (months, median [IQR]) | 58.3 [32.1, 138.1] | 84.7 [39.5, 183.9] | 45.4 [26.0, 83.8] | 108.4 [49.8, 160.2] | < 0.001 |
Death (%) | 38 (8.7) | 11 (5.6) | 25 (11.4) | 2 (8.7) | 0.112 |
Number of patients experiencing n relapse(s) (%) | |||||
0 | 343 (78.1) | 141 (71.9) | 188 (85.5) | 14 (60.9) | |
1 | 67 (15.3) | 37 (18.9) | 26 (11.8) | 4 (17.4) | |
2 | 20 (4.6) | 12 (6.1) | 4 (1.8) | 4 (17.4) | |
3 | 8 (1.8) | 5 (2.6) | 2 (0.9) | 1 (4.3) | |
4 | 1 (0.2) | 1 (0.5) | 0 (0) | 0 (0) |